AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+33.49%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.83B
AUM Growth
+$3.83B
(-44%)
Cap. Flow
-$4.23B
Cap. Flow
% of AUM
-110.43%
Top 10 Holdings %
Top 10 Hldgs %
84.96%
Holding
115
New
10
Increased
27
Reduced
10
Closed
11
Top Buys
| 1 |
Scholar Rock
SRRK
|
$37.4M |
| 2 |
Lexicon Pharmaceuticals
LXRX
|
$23.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$15.9M |
| 4 |
AUTL
Autolus Therapeutics
AUTL
|
$14.1M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
$13.3M |
Top Sells
| 1 |
BUFF
Blue Buffalo Pet Products, Inc
BUFF
|
$3.48B |
| 2 |
WW
WW International
WW
|
$872M |
| 3 |
Incyte
INCY
|
$25M |
| 4 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$19.8M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$12.6M |
Sector Composition
| 1 | Consumer Discretionary | 54.99% |
| 2 | Healthcare | 44.37% |
| 3 | Energy | 0% |
| 4 | Financials | 0% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
argenx
ARGX
$43.6B
| $12.4M | 0.26% | 150,000 | – | – |
|
27
Larimar Therapeutics
LRMR
$310M
| $12.3M | 0.26% | 1,200,000 | – | – |
|
|
AXDX
28
DELISTED
Accelerate Diagnostics
AXDX
| $11.2M | 0.24% | 500,000 | – | – |
|
29
ProQR Therapeutics
PRQR
$237M
| $11M | 0.23% | 1,500,000 -400,000 | -21% | -$2.92M |
|
30
Regenxbio
RGNX
$451M
| $10.8M | 0.23% | 150,000 -100,000 | -40% | -$7.18M |
|
|
CBAY
31
DELISTED
Cymabay Therapeutics
CBAY
| $10.7M | 0.23% | 800,000 +400,000 | +100% | +$5.37M |
|
|
GBT
32
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $9.04M | 0.19% | 200,000 | – | – |
|
|
BOLD
33
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.02M | 0.19% | 236,000 +86,000 | +57% | +$3.29M |
|
34
Iovance Biotherapeutics
IOVA
$807M
| $8.96M | 0.19% | 700,000 +240,000 | +52% | +$3.07M |
|
35
Solid Biosciences
SLDB
$427M
| $8.91M | 0.19% | 250,000 +100,000 | +67% | +$3.56M |
|
36
Rocket Pharmaceuticals
RCKT
$354M
| $7.85M | 0.17% | 400,000 +150,000 | +60% | +$2.94M |
|
37
Denali Therapeutics
DNLI
$2.23B
| $7.63M | 0.16% | 500,000 +50,000 | +11% | +$763K |
|
|
LJPC
38
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $7.29M | 0.16% | 250,000 -50,000 | -17% | -$1.46M |
|
39
Immunic
IMUX
$80.9M
| $6.85M | 0.15% | 1,000,000 | – | – |
|
40
Cartesian Therapeutics
RNAC
$261M
| $6.63M | 0.14% | 500,000 +375,000 | +300% | +$4.97M |
|
|
WHWK
41
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $6.47M | 0.14% | +1,558,400 | New | +$6.47M |
|
|
STML
42
DELISTED
Stemline Therapeutics, Inc.
STML
| $6.42M | 0.14% | 400,000 | – | – |
|
|
TBIO
43
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $6.33M | 0.13% | +500,000 | New | +$6.33M |
|
|
AGEN
44
Agenus
AGEN
$133M
| $6.24M | 0.13% | 2,750,000 | – | – |
|
45
AC Immune
ACIU
$205M
| $5.59M | 0.12% | 600,000 | – | – |
|
46
TG Therapeutics
TGTX
$4.65B
| $5.26M | 0.11% | 400,000 +150,000 | +60% | +$1.97M |
|
|
DRNA
47
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5.21M | 0.11% | 425,000 | – | – |
|
48
Spero Therapeutics
SPRO
$116M
| $5.14M | 0.11% | 350,000 | – | – |
|
49
Adicet Bio
ACET
$59.9M
| $5.03M | 0.11% | 550,000 +100,000 | +22% | +$915K |
|
50
Akebia Therapeutics
AKBA
$833M
| $4.74M | 0.1% | 475,000 | – | – |
|